Adipotide

Adipotide (FTPP) is a chimeric synthetic peptidomimetic consisting of two functional domains joined by a glycine-glycine linker. The first domain is a 9-amino-acid homing sequence (CKGGRAKDC) that binds prohibitin (PHB) on the surface of vascular endothelial cells in white adipose tissue. The second domain is the (KLAKLAK)2 proapoptotic sequence that disrupts mitochondrial membranes upon receptor-mediated cell internalization. The full peptide sequence is CKGGRAKDC-GG-D(KLAKLAK)2.

The compound was developed using an in-vivo phage display technique. Researchers screened billions of random peptide sequences for ones that would home specifically to white adipose tissue vasculature. The CKGGRAKDC sequence repeatedly appeared in the blood vessels of fat tissue. The binding partner was identified as prohibitin, establishing PHB as a vascular marker of white fat.

The 2004 Nature Medicine paper showed that adipotide treatment in obese mice produced rapid and substantial weight loss with sustained reduction in fat mass. The effect persisted after discontinuation, suggesting durable adipose tissue reduction rather than temporary appetite suppression.

Adipotide has a two-step bipartite mechanism:

Prohibitin binding on adipose vasculature. The CKGGRAKDC homing domain binds prohibitin on vascular endothelial cells supplying white adipose tissue. The expression pattern provides selectivity for adipose vasculature.

Receptor-mediated internalization. After binding, the complex is internalized into the endothelial cell.

Mitochondrial membrane disruption. The (KLAKLAK)2 payload disrupts mitochondrial outer membrane integrity, triggering cytochrome c release.

Intrinsic apoptosis pathway. Cytochrome c release activates the caspase cascade and produces selective apoptosis of adipose vascular endothelial cells.

Secondary fat cell death. Fat cells deprived of vascular supply undergo secondary cell death through ischemia.

The mechanism is fundamentally different from every approved obesity drug. GLP-1 agonists, amylin analogs, and MC4R agonists work through appetite regulation. Adipotide works through tissue destruction.

Preclinical Evidence

Kolonin et al. (2004), Nature Medicine. "Reversal of obesity by targeted ablation of adipose tissue." Obese mice treated with adipotide showed rapid weight loss within days, substantial reduction in fat mass, persistence of effect after discontinuation, no significant lean mass loss, and apparent selectivity for adipose tissue over other vascular beds.

Rhesus monkey studies. Obese rhesus macaques showed substantial weight loss with adipotide treatment over multi-week dosing. Body composition analysis confirmed selective fat mass reduction.

Prostate cancer model. Adipotide treatment in obese prostate cancer mouse models produced reduced tumor growth alongside fat mass reduction.

Regulatory Status

No FDA approval, no EMA approval, no marketing authorization in any country.

No completed published human clinical trials. The 2012 to 2014 Phase 1 trial at MD Anderson did not produce published efficacy or safety data. No active commercial development has been announced as of May 2026.

Compounding status. Adipotide is not on the FDA Category 2 bulks list as of May 2026.

WADA status. Not currently on the WADA Prohibited List.

Adipotide entered Phase 1 clinical trials in 2012 (NCT01262664) at MD Anderson Cancer Center in obese men with metastatic castration-resistant prostate cancer. The dose-finding protocol started at 0.03 mg per kg subcutaneous injection daily for 28 days. The trial was sponsored by Arrowhead Research Corporation through its Ablaris Therapeutics subsidiary.

The trial was discontinued before efficacy or safety results were published in peer-reviewed format. The reasons for discontinuation have not been publicly disclosed, though preclinical findings of renal tubular changes in nonhuman primate kidneys at the 28-day study window are widely cited as a likely contributor.

Preclinical animal studies used wide dose ranges across mouse and rhesus macaque models. Typical mouse dosing was 1 to 5 mg per kg daily for 4 to 6 weeks. No FDA-approved adipotide dosing exists. The compound has no active commercial development program as of May 2026 and is not on the FDA Category 2 bulks list. Off-label adult use of an unproven vascular-targeted mitochondrial-disrupting payload is not supported by safety evidence.

The principal safety concern that may have driven the clinical-stage failure was renal toxicity.

Nonhuman primate 28-day study. Histological findings in rhesus macaque kidneys after adipotide treatment included tubular changes. The findings were described as reversible upon cessation of treatment in the 28-day study.

Renal clearance and the (KLAKLAK)2 payload. The peptide is processed renally. The (KLAKLAK)2 mitochondria-disrupting domain is not inherently selective for adipose tissue if delivered at sufficient concentration to renal tubular cells.

Cumulative dosing concerns. Obesity treatment would require chronic dosing, which raises questions about cumulative renal exposure beyond the 28-day primate study window.

Blood pressure changes. Some animal studies documented changes in blood pressure that may relate to the vascular-targeted mechanism affecting blood vessels beyond adipose tissue.

The renal safety concerns are mechanism-related rather than off-target adverse effects. This makes them harder to engineer around than typical safety issues.

Adipotide is fundamentally different from every approved or near-approved obesity drug.

Adipotide vs Semaglutide / Tirzepatide. Different mechanism class entirely. GLP-1 agonists work through appetite regulation. Adipotide works through tissue destruction. Semaglutide and tirzepatide produce 15 to 22 percent weight loss with established safety profiles. Adipotide produced substantial weight loss in animals but has not been clinically validated in humans.

Adipotide vs Cagrilintide / Petrelintide. Amylin analogs work through leptin sensitivity restoration. Different mechanism class.

Adipotide vs Setmelanotide. MC4R agonist works through hypothalamic appetite regulation. Different mechanism class.

Adipotide vs Liposuction. Surgical removal of fat tissue. Adipotide attempts to achieve a similar result pharmacologically through vascular ablation. Liposuction has the advantage of immediate localized fat removal without systemic exposure to a mitochondria-disrupting payload.

The fundamental positioning challenge for adipotide is that the approved obesity pharmacotherapy class has produced substantial efficacy through metabolically benign mechanisms. The competitive bar for a tissue-destruction approach is now much higher than it was in 2004 when the mechanism was first proposed.